Recent advances in polymyalgia rheumatica

C E Owen1,2, R R C Buchanan1, A Hoi1

  • 1Department of Rheumatology, Austin Health, Melbourne, Victoria, Australia.

Insights

Polymyalgia rheumatica (PMR) is an inflammatory disorder causing pain and stiffness in older adults. New imaging techniques and understanding of cytokines are improving PMR diagnosis and treatment.

Area of Science:

  • Rheumatology
  • Immunology
  • Medical Imaging

Background:

  • Polymyalgia rheumatica (PMR) is a chronic inflammatory condition affecting individuals over 50, presenting with subacute shoulder and pelvic girdle pain and morning stiffness.
  • Diagnosis relies on clinical presentation and inflammatory markers due to the absence of a definitive test.
  • PMR exhibits heterogeneity, with potential for misdiagnosis (e.g., late-onset rheumatoid arthritis) and a significant comorbidity with giant cell arteritis (16-21% of cases).

Purpose of the Study:

  • To provide an updated perspective on the pathogenesis and diagnosis of Polymyalgia Rheumatica.
  • To highlight the role of advanced imaging modalities in understanding PMR.
  • To explore future treatment strategies informed by key cytokine involvement.

Main Methods:

  • Review of current literature on Polymyalgia Rheumatica.
  • Focus on diagnostic advancements, including ultrasound and whole-body positron emission tomography/computed tomography (PET/CT).
  • Discussion of emerging insights into PMR pathogenesis and cytokine targets.

Main Results:

  • Revised classification criteria (2012 EULAR/ACR) aim to define a more homogeneous PMR population for research.
  • Advanced imaging, such as ultrasound and PET/CT, offers enhanced insights into PMR pathology.
  • Identification of key cytokines involved in PMR pathogenesis is paving the way for targeted therapies.

Conclusions:

  • PMR diagnosis remains a clinical challenge, necessitating improved diagnostic tools.
  • Imaging modalities are increasingly important for understanding PMR and differentiating it from other conditions.
  • Future PMR treatments will likely focus on specific cytokine pathways, offering potential for more effective management.

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
520
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.1K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.8K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.5K
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
549
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
327